Drug intelligence / Profile preview

APN201

Development stage: Phase 2
Lead developer: Apeiron Biologics
Modality: Recombinant Proteins and Enzymes, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Topical

Overview

APN201 is a liposomal formulation of recombinant human Cu/Zn-superoxide dismutase (rhSOD) developed by Apeiron Biologics. It is designed to prevent radiation-induced dermatitis in women undergoing radiation therapy for breast cancer. The drug functions by scavenging superoxide, hydroxyl, and other oxygenated free radicals, thereby mitigating the cellular damage caused by radiation.

Brand names: Lipoxysan
Other names: Liposomal Recombinant Human Cu/Zn-superoxide Dismutaserecombinant human superoxide dismutase (rhSOD) encapsulated in liposomal vesicles formulated as a hydrophilic gel

Beyond the preview

Go deeper on APN201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APN201.

Explore the full profile